Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is a Healthcare company (Biotechnology) with a market capitalization of $191M. The Maz Rating grades it against the other companies in its sector.
Artiva Biotherapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.86, Artiva Biotherapeutics, Inc. trades at 0.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -45.3%, return on invested capital of -31.9% and a free cash flow yield of -56.5%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 19.88. Over the past 52 weeks the share price ranged from $2.96 to $14.53, with a beta of 2.41.
Artiva Biotherapeutics, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 2 Buy and 3 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.